Sonoma Pharmaceuticals, Inc. (SNOA)
Pre-market:
| Previous close | 3.3000 |
| Open | 3.3950 |
| Bid | 3.1900 x 1200 |
| Ask | 3.3800 x 900 |
| Day's range | 3.1500 - 3.4700 |
| 52-week range | 2.5500 - 13.3600 |
| Volume | |
| Avg. volume | 81,893 |
| Market cap | 10.125M |
| Beta (5Y monthly) | 0.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.4160 |
| Earnings date | 14 Nov 2022 - 18 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce that U.S. EPA has Added Nanocyn® Hospital-Grade Disinfectant to List N for Use Against COVID-19
WOODSTOCK, Ga., June 01, 2022--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group DMCC, are pleased to announce that Nanocyn® hospital grade disinfectant has been added to the list of COVID-19 disinfectants main
- Business Wire
Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce EPA Approval for Nanocyn® Hospital-Grade Disinfectant in the U.S.
WOODSTOCK, Ga., May 03, 2022--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group DMCC, received EPA approval for Nanocyn® as a hospital-grade disinfectant in the United States. Nanocyn®, which is manufactured by
- Business Wire
Sonoma Pharmaceuticals Launches New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South Africa
WOODSTOCK, Ga., March 30, 2022--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, and dermatological conditions, today announced that it has launched Microdox®, an urinary tract infection catheter and bladder rinse in New Zealand, Australia and South Africa.
